EP2168968B1
(en)
|
2004-04-02 |
2017-08-23 |
OSI Pharmaceuticals, LLC |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
EP1951724B1
(en)
*
|
2005-11-17 |
2011-04-27 |
OSI Pharmaceuticals, Inc. |
FUSED BICYCLIC mTOR INHIBITORS
|
JP5512975B2
(ja)
*
|
2005-12-29 |
2014-06-04 |
アッヴィ・インコーポレイテッド |
タンパク質キナーゼ阻害薬
|
WO2007087395A2
(en)
*
|
2006-01-25 |
2007-08-02 |
Osi Pharmaceuticals, Inc. |
UNSATURATED mTOR INHIBITORS
|
US7553639B2
(en)
*
|
2006-01-31 |
2009-06-30 |
Elan Pharma International Limited |
Alpha-synuclein kinase
|
CA2647391C
(en)
|
2006-04-04 |
2015-12-29 |
The Regents Of The University Of California |
Kinase antagonists
|
US8124759B2
(en)
*
|
2007-05-09 |
2012-02-28 |
Abbott Laboratories |
Inhibitors of protein kinases
|
US20090023743A1
(en)
*
|
2007-05-09 |
2009-01-22 |
Abbott Laboratories |
Inhibitors of protein kinases
|
US20110160232A1
(en)
|
2007-10-04 |
2011-06-30 |
Pingda Ren |
Certain chemical entities and therapeutic uses thereof
|
KR101897881B1
(ko)
|
2008-01-04 |
2018-09-12 |
인텔리카인, 엘엘씨 |
특정 화학 물질, 조성물 및 방법
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US20110207796A1
(en)
*
|
2008-02-13 |
2011-08-25 |
Elan Pharma International Limited |
Alpha-synuclein kinase
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
EP2276763A1
(en)
*
|
2008-03-19 |
2011-01-26 |
OSI Pharmaceuticals, Inc. |
Mtor inhibitor salt forms
|
CL2009000904A1
(es)
|
2008-04-21 |
2010-04-30 |
Shionogi & Co |
Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
|
JP2011520970A
(ja)
*
|
2008-05-19 |
2011-07-21 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
置換されたイミダゾピラジン類およびイミダゾトリアジン類
|
KR20110017431A
(ko)
|
2008-06-10 |
2011-02-21 |
아보트 러보러터리즈 |
신규한 트리사이클릭 화합물
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
CN102124009B
(zh)
|
2008-07-08 |
2014-07-23 |
因特利凯公司 |
激酶抑制剂及其使用方法
|
US8703778B2
(en)
|
2008-09-26 |
2014-04-22 |
Intellikine Llc |
Heterocyclic kinase inhibitors
|
WO2010045542A2
(en)
|
2008-10-16 |
2010-04-22 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
US8476431B2
(en)
*
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
CN102405214A
(zh)
|
2009-04-20 |
2012-04-04 |
Osi药物有限责任公司 |
C-吡嗪-甲胺的制备
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
SG181147A1
(en)
*
|
2009-12-01 |
2012-07-30 |
Abbott Lab |
Novel tricyclic compounds
|
CR20170159A
(es)
|
2009-12-01 |
2017-06-26 |
Abbvie Inc |
Nuevos compuestos tricíclicos
|
EP2544672A1
(en)
|
2010-03-09 |
2013-01-16 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2571357B1
(en)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
WO2011156698A2
(en)
*
|
2010-06-11 |
2011-12-15 |
Abbott Laboratories |
NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8809349B2
(en)
|
2011-01-10 |
2014-08-19 |
Infinity Pharmaceuticals, Inc. |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
WO2012135631A1
(en)
*
|
2011-03-30 |
2012-10-04 |
Arrien Pharmaeuticals Llc |
Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
|
WO2013004551A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
JP6027611B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
AU2012302197B2
(en)
|
2011-08-29 |
2016-01-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
CN106831541B
(zh)
|
2011-11-18 |
2019-09-06 |
赫普泰雅治疗有限公司 |
毒蕈碱性m1受体激动剂
|
UY34484A
(es)
|
2011-12-15 |
2013-07-31 |
Bayer Ip Gmbh |
Benzotienilo-pirrolotriazinas disustituidas y sus usos
|
WO2013087647A1
(en)
|
2011-12-15 |
2013-06-20 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer
|
ES2581065T3
(es)
|
2012-02-23 |
2016-08-31 |
Bayer Intellectual Property Gmbh |
Benzotienil-pirrolotriazinas sustituidas y usos de las mismas
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
AU2013323426A1
(en)
|
2012-09-26 |
2015-04-23 |
The Regents Of The University Of California |
Modulation of ire1
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014153509A1
(en)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
JP6466924B2
(ja)
|
2013-10-04 |
2019-02-06 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
DK3119397T3
(da)
|
2014-03-19 |
2022-03-28 |
Infinity Pharmaceuticals Inc |
Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10023576B2
(en)
|
2014-10-22 |
2018-07-17 |
Bristol-Myers Squibb Company |
Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
|
US10214537B2
(en)
|
2014-10-22 |
2019-02-26 |
Bristol-Myers Squibb Company |
Bicyclic heteroaryl amine compounds
|
CN106146509A
(zh)
*
|
2015-03-24 |
2016-11-23 |
重庆大学 |
一种抑制乳腺癌增殖的化合物及其应用
|
GB201513743D0
(en)
|
2015-08-03 |
2015-09-16 |
Heptares Therapeutics Ltd |
Muscarinic agonists
|
KR20180058741A
(ko)
|
2015-09-14 |
2018-06-01 |
인피니티 파마슈티칼스, 인코포레이티드 |
이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
|
EP3362455A1
(en)
|
2015-10-16 |
2018-08-22 |
AbbVie Inc. |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
PE20190175A1
(es)
|
2016-03-28 |
2019-02-01 |
Incyte Corp |
Compuestos de pirrolotriazina como inhibidores de tam
|
BR122023026297A2
(pt)
|
2016-04-15 |
2024-01-16 |
Cancer Research Technology Limited |
Composto heterocíclico como inibidor de ret cinase, composição farmacêutica e seu uso
|
PL3442535T3
(pl)
|
2016-04-15 |
2022-10-24 |
Cancer Research Technology Limited |
Związki heterocykliczne jako inhibitory kinazy ret
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
GB201617454D0
(en)
|
2016-10-14 |
2016-11-30 |
Heptares Therapeutics Limited |
Pharmaceutical compounds
|
US10259787B2
(en)
|
2016-10-14 |
2019-04-16 |
Heptares Therapeutics Limited |
Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
|
KR20230146104A
(ko)
|
2016-11-18 |
2023-10-18 |
시스틱 파이브로시스 파운데이션 |
Cftr 강화제로서의 피롤로피리미딘
|
MX2019007135A
(es)
*
|
2016-12-16 |
2019-11-18 |
Cystic Fibrosis Found Therapeutics Inc |
Derivados de heteroarilo biciclico como potenciadores de cftr.
|
US11564922B2
(en)
|
2017-03-09 |
2023-01-31 |
Abbvie Inc. |
Methods of treating crohn's disease and ulcerative colitis
|
WO2018165581A1
(en)
|
2017-03-09 |
2018-09-13 |
Abbvie Inc. |
Methods of treating crohn's disease and ulcerative colitis
|
GB201705971D0
(en)
*
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
CN108003163B
(zh)
*
|
2017-11-30 |
2020-11-24 |
武汉九州钰民医药科技有限公司 |
用作激酶抑制剂的吡唑并嘧啶类化合物及其应用
|
GB201810239D0
(en)
|
2018-06-22 |
2018-08-08 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
GB201819960D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
GEP20237531B
(en)
*
|
2019-01-31 |
2023-08-25 |
Bayer Ag |
Monohydrate of rogaratinib hydrochloride and solid states thereof
|
GB202020191D0
(en)
|
2020-12-18 |
2021-02-03 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
AU2020290049A1
(en)
*
|
2019-06-12 |
2022-02-03 |
Tmem16A Limited |
Compounds for treating respiratory disease
|
CN112300180B
(zh)
|
2019-07-26 |
2022-04-29 |
珠海宇繁生物科技有限责任公司 |
一种irak4激酶抑制剂及其制备方法
|